Ursodeoxycholic Acid Powder Cas No.128-13-2

Our high-purity ursodeoxycholic acid API (CAS 128-13-2), produced using advanced synthesis technology, is specifically developed to meet the stringent global pharmaceutical industry demands for critical bile acid APIs. The product achieves ≥98% HPLC quantitative purity (with ≥99% high-specification batches available), conforming to major pharmacopoeia standards including CP/USP/EP. It ensures molecular structural consistency (C₂₄H₄₀O₄) and low impurity residues (individual unknown impurities ≤0.1%). Manufacturing adheres to pharmaceutical GMP management systems, ensuring full traceability from raw material sourcing to finished product testing and consistent batch-to-batch stability.

Cholesterol Dissolution： Reduces cholesterol saturation in bile, promoting dissolution of cholesterol gallstones.

Hepatocyte Protection： Replaces toxic bile acids (e.g., lithocholic acid), mitigating hepatocyte membrane damage.

Improved Biliary Stasis： Stimulates bile secretion, alleviating cholestatic liver injury.

Immune Modulation： Suppresses abnormal MHC expression in hepatocytes, reducing autoimmune responses.

Primary Biliary Cholangitis (PBC) → First-line therapeutic agent (slows disease progression, improves biochemical markers).

Cholesterol Gallstones → Indicated for functional gallbladder stones in inoperable patients (lithotripsy therapy).

Based on these mechanisms, UDCA produces the following comprehensive pharmacological effects in vivo:

• Cholagogue and Hepatoprotective: UDCA exerts traditional cholagogue and hepatoprotective effects by promoting bile acid excretion and displacing toxic bile acids.

• Anti-inflammatory and Antioxidant: UDCA demonstrates anti-inflammatory and protective actions in human gastrointestinal epithelial cells.

• Improved Gallbladder Function: In patients with gallstones, UDCA supplementation significantly enhances gallbladder smooth muscle contractility.